Antibody-drug Conjugates

Technical Insights into 15 ADC Drugs and Future Innovations

by
Technical Insights into 15 ADC Drugs and Future Innovations

GUIDE Editor’s Recommendation Antibody-drug conjugates (ADC) remained popular in 2022. Enhertu redefined the treatment landscape for HER2 breast cancer, making headlines at major academic conferences like ASCO and ESMO; Kelun-Biotech approached a $10 billion license-out deal with multinational pharmaceutical company Merck, setting a new record for local pharmaceutical companies going abroad; the world’s first anti-CD79b … Read more

The Amazing ‘Magic Bullet’ – Antibody-Drug Conjugates (ADCs)

by
The Amazing 'Magic Bullet' - Antibody-Drug Conjugates (ADCs)

The Concept and Development History of ADC The treatment of tumors has always undergone a continuous transformation from theory to application, breaking and transforming again. As early as a century ago, scholars proposed the concept of antibody-drug conjugates (ADCs), vividly calling them “magic bullets,” aimed at targeting specific antigens that may exist on the surface … Read more

In-Depth Analysis of Antibody-Drug Conjugates (ADC) – Part 3

by
In-Depth Analysis of Antibody-Drug Conjugates (ADC) - Part 3

Introduction Antibody-drug conjugates (ADCs) are “biological bullets” formed by conjugating cytotoxic drugs (payloads) to antibodies via a “linker.” They consist of five components: target, antibody, linker, payload, and conjugation method. Each part is crucial to the function of ADCs, but today we will focus on the linker that connects the antibody and payload, examining the … Read more

Comprehensive Interpretation of Antibody-Drug Conjugates (ADC)

by
Comprehensive Interpretation of Antibody-Drug Conjugates (ADC)

Since the first use of cytotoxic chemicals to treat cancer, oncologists have been searching for ways to enhance efficacy without significantly increasing overall toxicity to patients. One of the methods attempted to improve the killing effect on tumor cells is the use of cytotoxic agents with potency at picomolar or lower levels (such as microtubule … Read more

ADC Technology: Innovations from Five Key Elements

by
ADC Technology: Innovations from Five Key Elements

History of ADC Drug Development Phase 1 (1906-1982), the concept of targeted therapy was proposed, and the technology took shape. Phase 2 (1983-2011), transition from clinical trials to commercialization, Mylotarg® was approved for market. Phase 3 (2012-present), explosive growth of ADC products. The five key elements of ADC drugs are target, antibody, linker, cytotoxic agent, … Read more

The Competitive Landscape Behind Coupling in Drug Development

by
The Competitive Landscape Behind Coupling in Drug Development

To improve the DMPK characteristics, many studies have explored the coupling of PROTAC payloads with monoclonal antibodies to create a new molecule known as “Antibody-Drug Conjugates (DAC).” This allows for more effective delivery of PROTAC degraders in vivo. ▲ Structure of DAC (Image Source: Reference 1) Compared to PROTAC molecules, DAC has several potential advantages: … Read more

A Comprehensive Guide to Non-Clinical Pharmacology and Toxicology Assessment of ADCs

by
A Comprehensive Guide to Non-Clinical Pharmacology and Toxicology Assessment of ADCs

Recently, ADC (Antibody-Drug Conjugate) conferences have been held one after another, with major biotech companies competing to report their ADC pipelines. It is expected that 2024 will still be the main venue for ADCs. Developing an entry-level ADC seems not difficult, but evaluating the pharmacology and toxicology in the preclinical stage has become a top … Read more

Introduction to ADC: A Brief Overview of Clinical Pharmacology

by
Introduction to ADC: A Brief Overview of Clinical Pharmacology

Introduction Antibody-drug conjugates (ADC) are comprised of monoclonal antibodies that target specific antigens linked to small molecule cytotoxic drugs via a linker, combining the powerful killing effects of traditional small molecule chemotherapy with the tumor-targeting properties of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (trade name: Mylotarg)) was approved for the treatment of CD33-positive acute … Read more

Understanding Antibody-Drug Conjugates (ADCs) in Lung Cancer Treatment

by
Understanding Antibody-Drug Conjugates (ADCs) in Lung Cancer Treatment

Last week, while introducing the “Breakthroughs and Innovations in Lung Cancer Treatment” from the “AACR 2021 Annual Report on Anti-Cancer Progress”（>> Click to review）, I mentioned a popular research topic—Antibody-Drug Conjugates (ADCs), which saw two new ADCs approved and two ADCs expanding their indications in 2021. Some readers expressed a desire to learn more about … Read more

Understanding ADC: Overview, Antibody and Linker Selection

by
Understanding ADC: Overview, Antibody and Linker Selection

The development of ADC drugs has not been smooth sailing, with nearly 100 years of history since the concept of the “magic bullet” was proposed, but ultimately, the clouds have parted to reveal the moon. DS8201 has redefined ADC, but it is not the end of ADC drugs, rather a new beginning. A comprehensive understanding … Read more